Work

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-ct014

Authors: Peter J. O’Dwyer, Sarina A. Piha-Paul, Christopher French, Sara Harward, Gerladine Ferron-Brady, Yuehui Wu, Olena Barbash, Anastasia Wyce, Meg Annan, Thierry Horner, Nigel J. Parr, Rab K. Prinjha, Christopher Carpenter, Geoffrey Shapiro, Arindam Dhar, Christine Hann

Institutions: University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Harvard University, GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom), Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2491205940

Cites:

Cited by: 37

Related to: 10